Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. Co.'s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Co. is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. We show 12 historical shares outstanding datapoints in our coverage of MLYS's shares outstanding history.
Understanding the changing numbers of MLYS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MLYS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MLYS by allowing them to research MLYS shares outstanding history
as well as any other stock in our coverage universe. |
Free MLYS Email Alerts:
Video: Shares Outstanding Importance
